DSM-Firmenich completes EUR 540 million buyback. DSM-Firmenich stock loses 1.31 percent

Published on 10/01/2026 at 16:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Citi raised its target from EUR 106.00 to EUR 111.00 on September 25, 2026. DSM-Firmenich stock costs EUR 96.06 on October 1, 2026 after EUR 97.34.

Bauhaus-Poster mit geometrischen Formen, Molekül und Schriftzug SCIENCE — dsm-firmenich AG (ISIN CH1216478797) erscheint als geometrisches Bauhaus-Poster mit Molekülformen und dem Wort SCIENCE, Illustration mit AI erstellt.

DSM-Firmenich completed its EUR 540.0 million share repurchase program on October 1, 2026, while DSM-Firmenich stock was trading at EUR 96.06 at Lang & Schwarz at 4:39 p.m. CEST, down 1.31 percent from the EUR 97.34 prior close. The company plans to cancel 6,488,446 repurchased shares by the end of the first quarter of 2027, giving the capital action a measurable effect beyond the purchase itself.

Buyback removes 6.5 million shares

According to GlobeNewswire on October 1, 2026, dsm-firmenich repurchased 7,169,147 shares at an average price of EUR 75.32. The final purchases included 193,100 shares bought from September 28 through September 30, 2026 at an average EUR 98.62, for a total of EUR 19.0 million.

Of the program total, 6,488,446 shares are earmarked for cancellation and 680,701 shares cover commitments under share-based compensation plans. The release says issued shares will fall from 253,626,947 to 247,138,501, a reduction of 2.60 percent. That makes the cancellation the central investor consequence, because the repurchase changes the future share count rather than only supporting near-term demand.

Analyst target sits above the quote

Citi raised its DSM-Firmenich price target from EUR 106.00 to EUR 111.00 and kept a Buy rating on September 25, 2026, according to Markets Insider. The new target stands 15.55 percent above the Lang & Schwarz price, calculated against EUR 96.06, so the analyst action provides a separate valuation reference from the buyback.

The company describes itself as a nutrition, health, and beauty group listed on Euronext Amsterdam and SIX Swiss Exchange. Its continuing operations generate more than EUR 9.0 billion in revenue, according to the October 1, 2026 release, which also identifies operations in almost 60 countries.

Stock remains below its yearly high

The EUR 96.06 quote is 3.36 percent below the 52-week high of EUR 99.40 and well above the 52-week low of EUR 55.22, based on the October 1, 2026 market snapshot. DSM-Firmenich carries a market capitalization of EUR 23.7 billion on the same date. MarketScreener lists November 3, 2026 as the scheduled sales and revenue release for the third quarter of 2026.

Capital reduction sets the next marker

The next concrete milestone is the planned cancellation by the end of the first quarter of 2027. Until then, the completed EUR 540.0 million program, the 2.60 percent planned share-count reduction, and the EUR 111.00 Citi target give investors three dated reference points for assessing the stock.

DSM-Firmenich was trading at EUR 96.06 at Lang & Schwarz on October 1, 2026 at 4:39 p.m. CEST, down 1.31 percent versus the Lang & Schwarz prior close of EUR 97.34 on September 30, 2026. The further course of trading is shown by the continuously updated real-time quote of DSM-Firmenich stock.